

Ajanta Pharma

BSE SENSEX
29,788

S&P CNX
9,237

CMP: INR1,741 TP: INR2,028 (+16%)

Buy



Stock Info

Bloomberg	AJP IN
Equity Shares (m)	88.5
52-Week Range (INR)	2150/1400
1, 6, 12 Rel. Per (%)	-1/-17/-1
M.Cap. (INR b)	153.9
M.Cap. (USD b)	2.3
Avg Val, INRm	295
Free float (%)	26.2

Financials Snapshot (INR b)


Y/E Mar	2017E	2018E	2019E
Sales	20.1	22.6	27.5
EBITDA	6.8	7.7	9.4
NP	5.0	5.6	7.0
EPS (Rs)	56.0	63.8	79.6
EPS Gr. (%)	18.9	13.8	24.9
BV/Share (Rs)	179.5	233.0	299.9
RoE (%)	35.9	30.9	29.9
RoCE (%)	34.0	29.6	28.9
P/E (x)	31.0	27.3	21.8
P/BV (x)	9.7	7.5	5.8

Shareholding pattern (%)

As On	Dec-16	Sep-16	Dec-15
Promoter	73.8	73.8	73.8
DII	2.0	2.2	1.8
FII	10.4	10.2	8.9
Others	13.8	13.8	15.5

FII Includes depository receipts

Stock Performance (1-year)



Continues to perform well on regulatory front

US business story, anti-malaria base business intact

- AJP's Dahej facility has successfully cleared its first USFDA inspection, implying minimal regulatory risk in the medium term.
- We expect institutional anti-malaria sales to be similar to FY16 based on stable funding to Global fund and low probability of re-entry of Ipca in CY17.
- In FY17, AJP grew at 14.2%, outperforming the 10.1% growth in the domestic formulations market. We remain positive on the stock. Buy.

Dahej facility successfully clears first USFDA inspection

USFDA inspected AJP's Dahej facility over April 3-7, 2017. This was the first USFDA inspection of this facility. AJP has filed one ANDA from this facility, which triggered the inspection. USFDA issued 0 (zero) Form 483 observations at the end of the inspection. This implies minimal regulatory compliance risk for AJP over the medium term. Approval of the ANDA would depend on further USFDA review. We expect the time period for the review to be 12-15 months. AJP's Paithan facility was also recently inspected and USFDA had issued one observation. We believe this observation to be minor in nature. With both formulations facilities successfully clearing USFDA inspection in the recent past, we believe AJP is well-placed on the regulatory front. Several of its peers are facing regulatory hurdles, which is impacting their business.

We expect share in Global Fund's anti-malaria procurements to remain intact

Given the scenario wherein funding to Global fund is stable compared to past year and continuing regulatory hurdle for Ipca lab, we expect similar volume of institutional anti-malaria business to AJP for CY17. There is high probability that there could be rollover of CY16 tender, implying pricing would also be similar to last year. Thus, we expect, value-wise, the institutional anti-malaria business to remain intact for AJP for CY17.

Continues to grow faster than domestic formulations (DF) industry

According to AIOCD, AJP grew at 14.2% compared to industry growth of 10.1% for FY17. With new product launches, increased traction in existing products and minimal impact of pricing cuts by NPPA, AJP continues to consistently outperform the industry. In addition to ophthalmology, cardiology and dermatology, AJP has started getting good traction in the pain segment as well.

Remain positive; reiterate Buy

We remain positive on AJP due to healthy pipeline and aggressive filing pace for next 2-3 years in the US market, sustained outperformance in the domestic formulations (DF) market and stable base in the Africa market. We expect 19% CAGR in earnings over FY17-20, led by a 46% CAGR in US sales and a 20.4% CAGR in DF sales. We value AJP at 25x FY19E EPS to arrive at a price target of INR2,028. **Buy.**

Tushar Manudhane (Tushar.Manudhane@MotilalOswal.com); +91 022 6129 1536

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Financials and Valuations

Consolidated - Income Statement

(INR Million)

Y/E March	FY13	FY14	FY15	FY16	FY17E	FY18E	FY19E	FY20E
Total Income from Operations	9,369	12,160	14,852	17,429	20,101	22,563	27,516	33,485
Change (%)	36.7	29.8	22.1	17.4	15.3	12.2	21.9	21.7
Total Expenditure	7,064	8,396	9,683	11,468	13,319	14,892	18,105	21,999
% of Sales	75.4	69.0	65.2	65.8	66.3	66.0	65.8	65.7
EBITDA	2,305	3,764	5,169	5,961	6,782	7,672	9,410	11,485
Margin (%)	24.6	31.0	34.8	34.2	33.7	34.0	34.2	34.3
Depreciation	342	439	516	451	568	710	832	954
EBIT	1,964	3,325	4,652	5,511	6,214	6,961	8,578	10,531
Int. and Finance Charges	191	87	59	49	58	47	46	46
Other Income	56	137	168	166	281	316	385	469
PBT bef. EO Exp.	1,828	3,375	4,761	5,628	6,438	7,230	8,917	10,953
EO Items	0	0	-85	0	0	0	0	0
PBT after EO Exp.	1,828	3,375	4,677	5,628	6,438	7,230	8,917	10,953
Total Tax	647	960	1,462	1,460	1,481	1,591	1,873	2,191
Tax Rate (%)	35.4	28.4	31.3	25.9	23.0	22.0	21.0	20.0
Reported PAT	1,182	2,415	3,215	4,168	4,957	5,639	7,044	8,763
Adjusted PAT	1,182	2,415	3,273	4,168	4,957	5,639	7,044	8,763
Change (%)	33.4	104.4	35.5	27.3	18.9	13.8	24.9	24.4
Margin (%)	12.6	19.9	22.0	23.9	24.7	25.0	25.6	26.2

Consolidated - Balance Sheet

(INR Million)

Y/E March	FY13	FY14	FY15	FY16	FY17E	FY18E	FY19E	FY20E
Equity Share Capital	118	177	177	177	177	177	177	177
Total Reserves	3,816	5,756	8,234	11,544	15,698	20,436	26,346	33,670
Net Worth	3,934	5,933	8,411	11,721	15,875	20,613	26,523	33,847
Total Loans	1,248	1,305	724	929	929	929	929	929
Deferred Tax Liabilities	237	230	152	200	200	200	200	200
Capital Employed	5,419	7,468	9,286	12,850	17,004	21,742	27,653	34,976
Gross Block	4,385	4,903	5,499	7,242	10,560	13,514	16,475	19,467
Less: Accum. Deprn.	1,659	2,109	2,618	2,726	3,294	4,004	4,836	5,791
Net Fixed Assets	2,726	2,794	2,881	4,516	7,266	9,510	11,638	13,676
Capital WIP	125	936	1,702	2,398	1,880	1,826	1,865	1,873
Total Investments	85	635	595	664	664	664	664	664
Curr. Assets, Loans&Adv.	4,247	5,130	6,286	7,237	9,473	12,292	16,587	22,533
Inventory	1,476	1,554	1,590	2,046	2,376	2,657	3,230	3,924
Account Receivables	1,505	2,022	2,588	3,724	4,294	4,820	5,878	7,154
Cash and Bank Balance	462	604	1,368	550	1,745	3,627	6,030	9,692
Loans and Advances	804	949	740	918	1,058	1,188	1,449	1,763
Curr. Liability & Prov.	1,763	2,026	2,177	1,965	2,279	2,550	3,102	3,770
Account Payables	1,317	1,245	1,298	1,650	1,916	2,142	2,604	3,164
Other Current Liabilities	217	325	188	176	203	227	277	338
Provisions	229	455	691	139	161	180	220	268
Net Current Assets	2,484	3,104	4,108	5,272	7,194	9,742	13,485	18,763
Appl. of Funds	5,419	7,468	9,286	12,850	17,004	21,742	27,653	34,976

E: MOSL Estimates

Financials and Valuations

Ratios

Y/E March	FY13	FY14	FY15	FY16	FY17E	FY18E	FY19E	FY20E
Basic (INR)								
EPS	13.4	27.3	37.0	47.1	56.0	63.8	79.6	99.1
Cash EPS	17.2	32.3	42.8	52.2	62.5	71.8	89.1	109.9
BV/Share	44.5	67.1	95.1	132.5	179.5	233.0	299.9	382.7
DPS	1.7	4.0	6.0	8.0	8.4	9.4	11.8	15.0
Payout (%)	14.5	17.0	18.2	18.4	16.2	16.0	16.1	16.4
Valuation (x)								
P/E			47.0	36.9	31.0	27.3	21.8	17.6
Cash P/E			40.6	33.3	27.9	24.2	19.5	15.8
P/BV			18.3	13.1	9.7	7.5	5.8	4.5
EV/Sales			10.3	8.9	7.6	6.7	5.4	4.3
EV/EBITDA			29.7	25.9	22.6	19.7	15.8	12.6
Dividend Yield (%)			0.3	0.5	0.5	0.5	0.7	0.9
FCF per share			19.9	3.4	20.1	28.4	36.2	52.9
Return Ratios (%)								
RoE	34.2	49.0	45.6	41.4	35.9	30.9	29.9	29.0
RoCE	25.7	39.9	40.5	38.6	34.0	29.6	28.9	28.3
RoIC	26.2	47.4	58.6	54.9	43.6	38.3	39.0	40.3
Working Capital Ratios								
Asset Turnover (x)	1.7	1.6	1.6	1.4	1.2	1.0	1.0	1.0
Inventory (Days)	58	47	39	43	43	43	43	43
Debtor (Days)	59	61	64	78	78	78	78	78
Creditor (Days)	51	37	32	35	35	35	35	34
Leverage Ratio (x)								
Net Debt/Equity	0.2	0.0	-0.1	0.0	-0.1	-0.2	-0.2	-0.3

Consolidated - Cash Flow Statement

(INR Million)

Y/E March	FY13	FY14	FY15	FY16	FY17E	FY18E	FY19E	FY20E
OP/(Loss) before Tax	1,635	3,299	4,560	5,474	6,438	7,230	8,917	10,953
Depreciation	342	439	516	451	568	710	832	954
Interest & Finance Charges	191	87	59	49	-224	-268	-339	-422
Direct Taxes Paid	-331	-937	-1,461	-1,614	-1,481	-1,591	-1,873	-2,191
(Inc)/Dec in WC	386	-745	-817	-1,235	-727	-666	-1,340	-1,616
CF from Operations	2,223	2,142	2,858	3,125	4,574	5,415	6,198	7,678
Others	120	-18	-64	139	0	0	0	0
CF from Operating incl EO	2,343	2,124	2,794	3,264	4,574	5,415	6,198	7,678
(Inc)/Dec in FA	-1,037	-1,878	-1,036	-2,962	-2,800	-2,900	-3,000	-3,000
Free Cash Flow	1,306	246	1,759	302	1,774	2,515	3,198	4,678
(Pur)/Sale of Investments	0	0	-45	-69	0	0	0	0
Others	87	97	102	135	281	316	385	469
CF from Investments	-950	-1,781	-979	-2,896	-2,519	-2,584	-2,615	-2,531
Inc/(Dec) in Debt	-748	57	-581	206	0	0	0	0
Interest Paid	-195	-87	-60	-49	-58	-47	-46	-46
Dividend Paid	-102	-171	-411	-1,343	-803	-901	-1,134	-1,439
CF from Fin. Activity	-1,045	-201	-1,052	-1,186	-861	-949	-1,180	-1,485
Inc/Dec of Cash	348	142	764	-818	1,195	1,883	2,403	3,662
Opening Balance	115	462	604	1,368	550	1,745	3,627	6,030
Closing Balance	462	604	1,368	550	1,745	3,627	6,030	9,692

Disclosures

This document has been prepared by Motilal Oswal Securities Limited (hereinafter referred to as Most) to provide information about the company (ies) and/or sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and does not constitute to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOST) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur.

MOST and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that MOST and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on twin parameters of performance & profitability of MOST.

MOST generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOST generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest. MOST and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the affiliates of MOST even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition MOST has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOST or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOST or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOST or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOST's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOST and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOST and/or its affiliates from doing so. MOST or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOST or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents.

Most and its associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Most and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Subject Company may have been a client of Most or its associates during twelve months preceding the date of distribution of the research report

MOST and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1% at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, MOST has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Motilal Oswal Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00000412

Pending Regulatory inspections against Motilal Oswal Securities Limited:

SEBI pursuant to a complaint from client Shri C.R. Mohanraj alleging unauthorized trading, issued a letter dated 29th April 2014 to MOSL notifying appointment of an Adjudicating Officer as per SEBI regulations to hold inquiry and adjudge violation of SEBI Regulations; MOSL replied to the Show Cause Notice whereby SEBI granted us an opportunity of Inspection of Documents. Since all the documents requested by us were not covered we have requested to SEBI vide our letter dated June 23, 2015 to provide pending list of documents for inspection.

List of associate companies of Motilal Oswal Securities Limited - [Click here to access detailed report](#)

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOST research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues

Disclosure of Interest Statement

Ajanta Pharma

- Analyst ownership of the stock
- Served as an officer, director or employee -

No
No

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOST & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong: This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Kong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part 1 of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons.

This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act (FAA) read with regulation 17(1)(d) of the Financial Advisers Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time.

In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:

Varun Kumar

Varun.kumar@motilalosal.com

Contact : (+65) 68189232

Office Address: 21 (Suite 31), 16 Collyer Quay, Singapore 04931



Motilal Oswal Securities Ltd

Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025

Phone: +91 22 3982 5500 E-mail: reports@motilalosal.com